Matthew Pauls
CIK 1573429 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.73M
Companies
7
Total Filings
49
Lifetime Open-Market Net
-$798.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTHS | Director | 14,364 | $27.77 | $398.9K | -$37.0K | 5 | 2026-07-07 |
| PVLA | Director | — | $142.84 | — | $0 | 1 | 2026-07-01 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | Director | 0 | $53.01 | $0 | -$424.8K | 5 | 2026-05-18 |
| SVRA | CHIEF EXECUTIVE OFFICER | 1,188,050 | $5.33 | $6.33M | -$336.5K | 21 | 2025-12-16 |
| Strongbridge Biopharma plc (SBBP) Delisted | President & CEO | 72,608 | $2.00 | $145.2K | $0 | 3 | 2019-02-22 |
| MSTX | Director | — | $8.58 | — | $0 | 3 | 2017-01-23 |
| INSM | Chief Commercial Officer | — | $104.13 | — | $0 | 3 | 2014-01-14 |
Recent Filings · Page 4 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-12-17 | SVRA | Grant (A) | — | $0 | EDGAR |
| 2020-09-15 | SVRA | Mixed | +227,922 | $0 | EDGAR |
| 2020-05-21 | — | Disp (D) | −26,953 | $0 | |
| 2020-04-28 | — | Mixed | +4,862 | $8.5K | |
| 2020-04-24 | — | Mixed | +5,715 | $10.0K | |
| 2020-03-05 | — | Grant (A) | +13,620 | $0 | |
| 2019-12-26 | SVRA | Grant (A) | — | $0 | EDGAR |
| 2019-04-24 | — | Grant (A) | +20,000 | $0 | |
| 2019-02-22 | Strongbridge Biopharma plc (SBBP) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
| 2018-12-14 | SVRA | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.